DR BRUCE CAMPBELL
Bruce Campbell Bsc, PhD Chem FRSC has more than 45 years of drug development experience and has developed 13 drugs or vaccines in a wide range of indications which have made it to the market. Formerly R and D Director at Servier (UK), Senior VP of Research and Development at Neurocrine Biosciences, Inc (US) , Chief Scientific Officer at IP2IPO (IPGroup), Founder, Chairman and Head of Development for Proximagen Ltd, he currently acts as a consultant to various pharmaceutical companies in Europe and the USA. Although his expertise is in Pharmacokinetics, metabolism, clinical pharmacology and non clinical safety studies he has been responsible for all aspects of drug development from chemistry, manufacturing to regulatory and phase III clinical trials and even withdrawal of drugs from the market . His disease areas of expertise include CNS, Pain, Insomnia, CVS, Respiratory, Cancer, Women's Health, Arthritis, Metabolism ( Obesity, Diabetes, Lipids), Muscular Dystrophy and vaccines.
In addition, he has been on the board of Proximagen, IPGroup, hVivo, Modern Biosciences Synairgen and IQur and has been a director and European Chairman of the Drug Information Association, and a member of the European ICH Safety Working Party helping to write ICH safety guidances He is a visiting Professor in Pharmacology at King's College, London and written more than 100 papers involving all aspects of drug development.